Skip to main content
. Author manuscript; available in PMC: 2008 Feb 20.
Published in final edited form as: Cancer Immunol Immunother. 1994 Aug;39(2):73–83. doi: 10.1007/BF01525312

Fig. 1.

Fig. 1

Flow-cytometric analysis of MHC and ICAM-1 molecule expression by the neuroblastoma line IMR-32. IMR-32 does not bind the mAb W6/32 (directed against a monomorphic determinant on HLA-A, -B, -C), MA2.2 (against HLA-A2 and -A29), anti-ICAM-I or anti-HLA-DR prior to IFNγ treatment. After IFNγ treatment (500 U/ml for 72 h), expression of MHC class I molecules (W6/32), HLA-A2 (MA2.2), and ICAM-1, but not HLA-DR, is detected